Tysabri
Named-patient access overview. Tysabri is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Tysabri (natalizumab) is a humanized anti-alpha4-integrin monoclonal antibody developed by Biogen. The US Food and Drug Administration first approved Tysabri in November 2004 for relapsing forms of multiple sclerosis, with an additional approval in January 2008 for moderately to severely active Crohn disease in adult patients with inadequate response to or intolerance of conventional therapies and inhibitors of TNF-alpha. The drug is administered as a 300 mg intravenous infusion every four weeks at a certified infusion centre under the TOUCH Prescribing Program because of the risk of progressive multifocal leukoencephalopathy. Reserve Meds coordinates physician-led cross-border sourcing for international patients.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Tysabri
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Tysabri is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Tysabri in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Tysabri
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.